Bookmark and Share
BioAssay: AID 588506

Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set

Assay Implementation: J Jacob Strouse, Susan Young, Stephanie Chavez, Dominique Perez, Matthew Garcia, Travis Houston, Keon Ahghar, Terry Foutz, Anna Waller, Annette Evangelisti, Mark Carter, Virginia Salas ..more
_
   
 Tested Compounds
 Tested Compounds
All(1993)
 
 
Active(129)
 
 
Inactive(1862)
 
 
Inconclusive(2)
 
 
 Tested Substances
 Tested Substances
All(1993)
 
 
Active(129)
 
 
Inactive(1862)
 
 
Inconclusive(2)
 
 
 Related BioAssays
 Related BioAssays
AID: 588506
Data Source: NMMLSC (UNMCMD_phenotypic_multiplex_HTS_for_antifungal efflux_pump_i..)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2011-10-13
Modify Date: 2012-03-09

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compounds: 129
Related Experiments
Show more
AIDNameTypeComment
485335Summary report for phenotypic HTS multiplex for antifungal efflux pump inhibitorsSummarydepositor-specified cross reference: Summary report for phenotypic HTS multiplex for antifungal efflux pump inhibitors
485275Phenotypic HTS multiplex for antifungal efflux pump inhibitorsScreeningsame project related to Summary assay
588517Compound fluorescence counter screen for HTS for inhibitors of efflux pump with Cherry Pick1 compound setScreeningsame project related to Summary assay
588518Flow Cytometric HTS singleplex for inhibitors of yeast efflux pump, specifically Mdr1 with Cherry Pick1 compound setScreeningsame project related to Summary assay
588520Flow Cytometric HTS singleplex for inhibitors of yeast efflux pump, specifically Cdr2 with Cherry Pick1 compound setScreeningsame project related to Summary assay
588522Flow Cytometric HTS singleplex for inhibitors of yeast efflux pump, specifically Cdr1 with Cherry Pick1 compound setScreeningsame project related to Summary assay
588604Dose Response HTS singleplex for inhibitors of yeast efflux pump, specifically Cdr2 with Hit compounds from Cherry Pick1Confirmatorysame project related to Summary assay
588606Dose Response HTS singleplex for inhibitors of yeast efflux pump, specifically Cdr1 with Hit compounds from Cherry Pick1Confirmatorysame project related to Summary assay
588608Dose Response HTS singleplex for inhibitors of yeast efflux pump, specifically Mdr1 with Hit compounds from Cherry Pick1Confirmatorysame project related to Summary assay
588620Dose response compound fluorescence counter screen for HTS for inhibitors of efflux pump with Hit compounds from Cherry Pick1Confirmatorysame project related to Summary assay
623992Dose Response HTS singleplex for inhibitors of yeast efflux pump, specifically Mdr1 with Cherry Pick2 compound setConfirmatorysame project related to Summary assay
623994Dose Response HTS singleplex for inhibitors of yeast efflux pump, specifically Cdr2 with Cherry Pick2 compound setConfirmatorysame project related to Summary assay
623996Dose Response HTS singleplex for inhibitors of yeast efflux pump, specifically Cdr1 with Cherry Pick2 compound setConfirmatorysame project related to Summary assay
Description:
UNM CMD Assay Overview:
Assay Support: 1 R03 MH087406-01A1
Project Title: Identification of broad-spectrum antifungal efflux pump inhibitors
PI: Richard Cannon
Screening Center PI: Larry Sklar / UNMCMD
Chemistry Center PI: Craig Lindsley

Assay Implementation: J Jacob Strouse, Susan Young, Stephanie Chavez, Dominique Perez, Matthew Garcia, Travis Houston, Keon Ahghar, Terry Foutz, Anna Waller, Annette Evangelisti, Mark Carter, Virginia Salas

Assay Background and Significance:

Fungal infections, exemplified by oral and invasive candidiasis, cause considerable morbidity and mortality in the immunocompromised. Treatment of patients with fungal infections is severely hampered by the development of antifungal drug resistance [Cannon, et al 2009]. The goal of this project is to address this health need by discovering novel chemical compounds that reverse antifungal drug resistance by inhibiting the drug efflux pump molecules in the fungal cell membrane, overexpression of which is the major cause of resistance in clinical isolates of most Candida species [Niimi, et al. 2004].

Utilizing a a panel of yeast strains expressing efflux pumps from the following clinically relevant fungi: Candida albicans, Candida glabrata, and Candida krusei [Lamping and Cannon, 2010], this approach analyzes three 'sentinel' strains in a phenotypic HTS which measures efflux of the fluorescent pump substrate Nile Red. Follow-up analysis on confirmed HTS hits will be conducted in single-plex assays using each strain individually to identify the target detected in the primary HTS.
Protocol
Yeast cultures (Saccharomyces cerevisiae strain AD1-8u background), expressing efflux pumps from Candida albicans, namely AD/CaCDR1; AD/CaCDR2 and AD/CaMDR1, and the control strain containing the empty pABC3 cassette without a heterologous efflux pump gene, AD/pABC3, (all supplied by the assay provider) are incubated at 30 degrees C with shaking (250 rpm) until an optical density (OD 600) of 1.5 to 2.0 is obtained. All cultures are adjusted to be at an equivalent OD of 0.6. The cells are collected by centrifugation and washed with PBS, then re-suspended as a tri-plex mixture in PBS with 10 microM Nile Red (Invitrogen USA). The mixture is placed at 4 degrees C to equilibrate with efflux pumps effectively turned off. Wells containing 5 microL of PBS with 2 percent glucose and 20 microM compound are plated during this time. Enniatin B is used as an on-plate positive control at 25 microM. Vector (AD/pABC3, stained in the same protocol as the tri-plex) is used as an off-plate control. The compound/buffer wells receive 5 microL of stained tri-plex mixture. In-well reagent summary: 5 microM Nile Red, 10 microM compound, 1 percent glucose. The assay plate is incubated inverted 30 degrees C for 1 hr. Accumulation of Nile Red is measured by sample delivery via HyperCyt (IntelliCyt, USA) to a Cyan (Beckman Coulter, USA) flow cytometer. Samples are excited with a 488 nm laser and a PE-Texas Red filter is used to detect the fluorescence signal from the Nile Red substrate.

Calculation:
The data are exported into a Microsoft Excel spreadsheet template, and the PERCENT_RESPONSE is calculated for each well as follows:

PERCENT_RESPONSE = 100((MFItest-MFIneg.control)/(MFIpos.control-MFIneg.control))
where MFI is median fluorescence intensity of cells with test compounds, positive or negative control wells.

RAW_MEDIAN = median fluorescence intensity of cells per well

Cutoff for determining compound as active is based on compound having response value larger than 4 standard deviations of the overall response values measured for the entire Validation compound set, i.e., 0.02 + 4*0.13 = 0.42.

The PUBCHEM_ACTIVITY_SCORE is determined by multiplying response value with 100. Meaning Active compounds have PUBCHEM_ACTIVITY_SCORE greater than 42.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Response (10μM**)Percent inhibition of efflux pumpFloat%

** Test Concentration.
Additional Information
Grant Number: 1 R03 MH087406-01A1

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: